Dec 27,2022

Digital therapeutics will empower remote patient care in 2023

Digital therapeutics, or DTx, is a rapidly growing field that is poised to revolutionise the way we deliver remote patient care. By utilising mobile apps and other digital technologies, DTx offers a convenient and cost-effective alternative to traditional in-person therapies, empowering patients to take control of their own health and wellness. Software mobile health apps are now classified as medical devices in Europe, requiring increased regulation and safety verification. These regulatory changes encourage consumer trust, uptake, and acceptance of these products as a legitimate form of medical care.

#software

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 30,2020

Biofourmis Partners with ImagineMIC to Pioneer Collaborative Remote Patient Monitoring Model

Biofourmis, a fast-growing global leader in digital medicine that powers personally predictive care, and ImagineMIC™ announced a partnership agreement today to drive improved outcomes and lower healthcare costs for patients with chronic conditions. ImagineMIC delivers chronic care management through remote monitoring services and HIPAA-compliant technology. The first phase of the collaboration includes integrating Biofourmis’ artificial intelligence (AI)-powered, FDA-cleared RhythmAnalytics® with ImagineMIC’s remote management technology, which is monitored by clinicians located in the ImagineMIC™ Monitoring Intervention Center (MIC) in New York State.

COLLABORATION PARTNERSHIP

#connected device

#software

#rpm

View Analyst & Ambassador Comments
Go to original news
Feb 25,2020

One Drop Increases Accuracy of AI-powered Hypoglycemia and Hyperglycemia Predictions and Introduces Alert Capability for People Using CGMs

One Drop, a leader in digital therapeutics solutions for people living with diabetes and other chronic conditions, presented new results for continuous glucose monitor-based glucose predictions at The 13th International Conference on Advanced Technologies & Treatments for Diabetes. One Drop’s patent-pending machine learning model accurately predicts the probabilities that a user’s glucose will rise above 180 mg/dL or fall below 70 mg/dL. At 30 minutes, the predictions are 99.5% accurate, at 1 hour, 98.6% accurate, and at 4 hours, One Drop’s accuracy is 91.9%

CLINICAL STUDY

#cgm

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Mar 27,2020

Q&A: A firsthand account of FDA's Pre-Cert Program

Yesterday, Pear Therapeutics announced the regulatory clearance of Somryst, its prescription digital therapeutic for chronic insomnia. MobiHealthNews spoke with Pear's chief medical officer, Dr. Yuri Maricich, about his company's experience clearing a digital health software product through the experimental program: What kinds of qualifications the FDA sought, the unexpected surprises Pear faced, and which digital health companies might be interested in pursuing precertification once the program has been finalized.

PRODUCT

#software

View Analyst & Ambassador Comments
Go to original news
Apr 09,2020

CureApp in Partnership with Jichi University of Medicine Launches the Phase 3 Clinical Trial for Hypertension Digital Therapeutics

CureApp, Inc. (Headquarters: Chuo-ku, Tokyo; President and CEO: Kohta Satake, MD) has launched a phase 3 multicenter randomized controlled study of Digital Therapeutics in the treatment of hypertension in Japan with a number of partners, including Kazuomi Kario, MD, professor of the Division of Cardiovascular Medicine, School of Medicine, Jichi Medical University , Ph.D. The study will evaluate the effectiveness and safety of Digital Therapeutics in patients with essential hypertension who have not yet been treated with oral antihypertensive drugs.

PRODUCT

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Apr 14,2020

As Demands for Remote, Self-Care Mental Health Support Grow Globally, Happify Health Launches Happify Connect™

Happify Health announced the launch of Happify Connect™, a new screening and referral hub that makes it easier for employees and health plan members to immediately access the mental health support they need from the security of their own homes. With the increasing demand for remote self-care, Happify Connect powers an experience that gives global employers and health plans the ability to deliver a unified, cohesive ecosystem of mental health solutions that address a variety of needs for differing severity levels. Happify Connect is a first line of engagement screening and referral solution that helps employers and health plans optimize their care strategies, reduce disengagements during care, improve overall outcomes and reduce cost of care by leveraging digital innovation.

PRODUCT

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Apr 15,2020

Swiss hospitals implement remote COVID-19 symptom checking platform

Digital oncological therapeutics company Kaiku Health has developed a symptom monitoring system for patients with coronavirus to be used by Geneva University Hospitals (HUG). The platform will assist HUG in triaging patients who suspect they have the virus or who have already been diagnosed, both in and out of hospital.

PRODUCT

#rpm

#software

View Analyst & Ambassador Comments
Go to original news
Apr 17,2020

MedRhythms Announces an Expansion of Intellectual Property Portfolio, Securing Patent on Audio Engine for Digital Therapeutics Platform

MedRhythms, a Portland, Maine-based company building direct stimulation digital therapeutics that use sensors, software, and music to measure and improve walking, announced today the issuance of patent US20190022351A1 by the United States Patent and Trademark Office (USPTO). This is the second granted patent in MedRhythms' portfolio. The patent, entitled "Enhancing Music for Repetitive Motion Activities," covers the audio engine enabling MedRhythms' digital therapeutics platform.

PRODUCT

#software

#connected device

View Analyst & Ambassador Comments
Go to original news
Apr 20,2020

Novartis acquires digital therapeutic using video games, 3D glasses to treat 'lazy eye'

Novartis announced this morning the acquisition of Amblyotech, a startup that combines 3D glasses and video game software to treat amblyopia, more commonly known as "lazy eye." The terms of the deal were not disclosed. Novartis also said that it will be developing new games and kicking off a proof-of-concept study alongside major French video game publisher Ubisoft and McGill University later this year.

COLLABORATION MERGERS & ACQUISITION

#product & service

#software

View Analyst & Ambassador Comments
Go to original news
Jun 03,2020

BlueStar's eighth FDA clearance adds long-acting basal insulin support for Type 2 patients

WellDoc's BlueStar chronic disease-management tool has picked up another 510(k) FDA clearance that will allow it to support adult Type 2 diabetes patients using long-acting basal insulin. The feature was announced by WellDoc this morning, but cleared by the agency in April, according to a listing on its website. The new capability takes the form of a new program within the prescription BlueStar app, called the Insulin Adjustment Program. Healthcare providers use a web-based interface to prescribe an initial dose of long-acting basal insulin, which the new feature then uses to guide patients with subsequent titrations.

REGULATORY FDA

#software

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to SOFTWARE